 Richard Vandivier
Concepts (442)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 21 | 2025 | 1075 | 3.040 |
Why?
| | Apoptosis | 23 | 2014 | 2446 | 2.100 |
Why?
| | Phagocytosis | 15 | 2014 | 297 | 1.930 |
Why?
| | Macrophages, Alveolar | 14 | 2019 | 372 | 1.160 |
Why?
| | Tobacco Smoke Pollution | 3 | 2022 | 236 | 1.110 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 238 | 0.990 |
Why?
| | Pulmonary Embolism | 2 | 2018 | 238 | 0.950 |
Why?
| | Respiratory Insufficiency | 4 | 2024 | 333 | 0.850 |
Why?
| | Lung | 13 | 2025 | 4143 | 0.690 |
Why?
| | Smoking | 5 | 2018 | 1556 | 0.690 |
Why?
| | Adrenal Cortex Hormones | 2 | 2015 | 500 | 0.680 |
Why?
| | Cigarette Smoking | 2 | 2025 | 104 | 0.660 |
Why?
| | rhoA GTP-Binding Protein | 6 | 2014 | 77 | 0.620 |
Why?
| | Pulmonary Ventilation | 2 | 2018 | 84 | 0.590 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 375 | 0.550 |
Why?
| | Pneumonia | 6 | 2023 | 641 | 0.520 |
Why?
| | Intensive Care Units | 7 | 2025 | 905 | 0.510 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2011 | 300 | 0.500 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 285 | 0.470 |
Why?
| | rac1 GTP-Binding Protein | 3 | 2012 | 55 | 0.430 |
Why?
| | Pulmonary Alveoli | 4 | 2016 | 390 | 0.430 |
Why?
| | Stem Cells | 2 | 2018 | 622 | 0.420 |
Why?
| | Methylprednisolone | 1 | 2014 | 63 | 0.410 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 61 | 0.410 |
Why?
| | Critical Illness | 8 | 2020 | 880 | 0.400 |
Why?
| | Patient Admission | 2 | 2025 | 206 | 0.400 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 5 | 2016 | 31 | 0.390 |
Why?
| | Asthma | 3 | 2022 | 1915 | 0.390 |
Why?
| | Hospital Mortality | 6 | 2025 | 975 | 0.390 |
Why?
| | Bronchiectasis | 2 | 2006 | 112 | 0.380 |
Why?
| | Hypnotics and Sedatives | 2 | 2025 | 215 | 0.370 |
Why?
| | Hospitalization | 6 | 2025 | 2340 | 0.370 |
Why?
| | Case Management | 1 | 2012 | 65 | 0.370 |
Why?
| | Alcoholism | 5 | 2023 | 814 | 0.370 |
Why?
| | Coronary Disease | 1 | 2015 | 369 | 0.370 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2016 | 559 | 0.370 |
Why?
| | Humans | 68 | 2025 | 143821 | 0.360 |
Why?
| | rho GTP-Binding Proteins | 2 | 2010 | 56 | 0.360 |
Why?
| | Serotonin | 1 | 2014 | 293 | 0.350 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 72 | 0.350 |
Why?
| | Noninvasive Ventilation | 2 | 2024 | 65 | 0.340 |
Why?
| | Cystic Fibrosis | 4 | 2006 | 1118 | 0.330 |
Why?
| | Pulmonary Surfactant-Associated Protein A | 3 | 2008 | 30 | 0.320 |
Why?
| | Patient Education as Topic | 2 | 2012 | 791 | 0.310 |
Why?
| | Inflammation Mediators | 4 | 2016 | 511 | 0.300 |
Why?
| | Neutrophils | 7 | 2010 | 1144 | 0.290 |
Why?
| | Male | 39 | 2025 | 71569 | 0.280 |
Why?
| | Mice | 21 | 2017 | 18421 | 0.280 |
Why?
| | Jurkat Cells | 6 | 2012 | 118 | 0.280 |
Why?
| | Interleukin-8 | 1 | 2009 | 273 | 0.280 |
Why?
| | Female | 37 | 2025 | 77570 | 0.270 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 3 | 2006 | 13 | 0.270 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2018 | 2030 | 0.270 |
Why?
| | Signal Transduction | 6 | 2014 | 5241 | 0.260 |
Why?
| | Middle Aged | 24 | 2025 | 35630 | 0.260 |
Why?
| | Cells, Cultured | 9 | 2016 | 4172 | 0.260 |
Why?
| | Benzodiazepines | 2 | 2025 | 154 | 0.260 |
Why?
| | Animals | 30 | 2017 | 38140 | 0.250 |
Why?
| | Acyl Coenzyme A | 1 | 2006 | 31 | 0.250 |
Why?
| | Intracellular Fluid | 1 | 2006 | 25 | 0.250 |
Why?
| | rho-Associated Kinases | 3 | 2014 | 83 | 0.250 |
Why?
| | Lovastatin | 1 | 2006 | 36 | 0.240 |
Why?
| | Retrospective Studies | 14 | 2025 | 16754 | 0.240 |
Why?
| | Lung Diseases, Obstructive | 1 | 2006 | 43 | 0.240 |
Why?
| | Substance-Related Disorders | 2 | 2025 | 1079 | 0.240 |
Why?
| | Collectins | 1 | 2006 | 6 | 0.240 |
Why?
| | Opsonin Proteins | 1 | 2006 | 19 | 0.240 |
Why?
| | Inflammation | 9 | 2016 | 2893 | 0.240 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2006 | 115 | 0.230 |
Why?
| | Quality of Life | 3 | 2022 | 3142 | 0.230 |
Why?
| | Self Care | 1 | 2009 | 398 | 0.230 |
Why?
| | Ethanol | 1 | 2010 | 626 | 0.230 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2009 | 358 | 0.230 |
Why?
| | Leukocyte Elastase | 2 | 2002 | 76 | 0.220 |
Why?
| | Neuromuscular Blockade | 1 | 2025 | 50 | 0.220 |
Why?
| | Mice, Knockout | 8 | 2014 | 3120 | 0.220 |
Why?
| | Propofol | 1 | 2025 | 89 | 0.220 |
Why?
| | Oligopeptides | 1 | 2006 | 267 | 0.210 |
Why?
| | Shock, Septic | 2 | 2022 | 216 | 0.210 |
Why?
| | Influenza A virus | 1 | 2025 | 112 | 0.210 |
Why?
| | Mice, Inbred C57BL | 11 | 2014 | 6032 | 0.210 |
Why?
| | Cohort Studies | 6 | 2022 | 5861 | 0.210 |
Why?
| | Complement C1q | 2 | 2006 | 33 | 0.200 |
Why?
| | Aged | 17 | 2025 | 25615 | 0.200 |
Why?
| | Ibuprofen | 4 | 2001 | 83 | 0.200 |
Why?
| | Disease Progression | 4 | 2020 | 2871 | 0.200 |
Why?
| | Erythropoietin | 1 | 2004 | 99 | 0.200 |
Why?
| | Lipopolysaccharides | 5 | 2016 | 873 | 0.200 |
Why?
| | Respiratory System | 2 | 2018 | 159 | 0.200 |
Why?
| | Calreticulin | 1 | 2002 | 22 | 0.190 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2025 | 467 | 0.190 |
Why?
| | Adult | 22 | 2025 | 40129 | 0.180 |
Why?
| | Extracellular Matrix | 1 | 2006 | 563 | 0.170 |
Why?
| | Patient Discharge | 2 | 2018 | 939 | 0.170 |
Why?
| | Smoke-Free Policy | 1 | 2021 | 13 | 0.170 |
Why?
| | Treatment Outcome | 5 | 2022 | 11459 | 0.160 |
Why?
| | Transforming Growth Factor beta | 4 | 2013 | 481 | 0.160 |
Why?
| | Macrophages | 5 | 2010 | 1508 | 0.160 |
Why?
| | Smokers | 2 | 2019 | 148 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 6 | 2009 | 1223 | 0.160 |
Why?
| | Mice, Inbred ICR | 3 | 2013 | 113 | 0.160 |
Why?
| | Endotoxins | 5 | 2013 | 214 | 0.160 |
Why?
| | Receptors, Cell Surface | 1 | 2002 | 380 | 0.150 |
Why?
| | Autoimmune Diseases | 2 | 2014 | 464 | 0.150 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1135 | 0.150 |
Why?
| | Granulomatous Disease, Chronic | 2 | 2010 | 49 | 0.150 |
Why?
| | Nitroprusside | 1 | 1999 | 72 | 0.150 |
Why?
| | Speech Therapy | 1 | 2019 | 21 | 0.150 |
Why?
| | Hexosaminidases | 1 | 2019 | 15 | 0.150 |
Why?
| | Influenza, Human | 1 | 2025 | 611 | 0.140 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 37 | 0.140 |
Why?
| | Macrolides | 1 | 2019 | 69 | 0.140 |
Why?
| | Pharmacoepidemiology | 2 | 2019 | 22 | 0.140 |
Why?
| | Vecuronium Bromide | 1 | 2018 | 7 | 0.140 |
Why?
| | Atracurium | 1 | 2018 | 14 | 0.140 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 24 | 0.140 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2018 | 25 | 0.140 |
Why?
| | Coronary Circulation | 1 | 2018 | 135 | 0.140 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 27 | 0.140 |
Why?
| | Cardiologists | 1 | 2018 | 46 | 0.140 |
Why?
| | Bronchoalveolar Lavage Fluid | 5 | 2016 | 644 | 0.140 |
Why?
| | Time | 1 | 2018 | 88 | 0.140 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 310 | 0.140 |
Why?
| | Counseling | 1 | 2021 | 400 | 0.130 |
Why?
| | Polyneuropathies | 1 | 2017 | 57 | 0.130 |
Why?
| | Occupational Therapy | 1 | 2019 | 112 | 0.130 |
Why?
| | Up-Regulation | 2 | 2019 | 863 | 0.130 |
Why?
| | Epithelium | 1 | 2018 | 316 | 0.130 |
Why?
| | Factor Xa Inhibitors | 1 | 2018 | 189 | 0.130 |
Why?
| | Aged, 80 and over | 7 | 2022 | 8130 | 0.130 |
Why?
| | Nitric Oxide | 3 | 2006 | 903 | 0.130 |
Why?
| | Disease Models, Animal | 5 | 2017 | 4553 | 0.120 |
Why?
| | Hypertension, Pulmonary | 4 | 2016 | 1981 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2018 | 767 | 0.120 |
Why?
| | Ventricular Function, Left | 2 | 2018 | 522 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1322 | 0.120 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 1901 | 0.120 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2018 | 224 | 0.120 |
Why?
| | Environmental Exposure | 1 | 2021 | 584 | 0.120 |
Why?
| | Propensity Score | 2 | 2017 | 359 | 0.120 |
Why?
| | Receptors, IgG | 2 | 2009 | 76 | 0.120 |
Why?
| | DNA, Bacterial | 1 | 2017 | 341 | 0.120 |
Why?
| | Critical Care | 2 | 2020 | 693 | 0.120 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 181 | 0.120 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 328 | 0.120 |
Why?
| | Antibodies, Monoclonal | 2 | 2014 | 1522 | 0.110 |
Why?
| | Length of Stay | 3 | 2019 | 1312 | 0.110 |
Why?
| | Respiratory Mucosa | 2 | 2009 | 326 | 0.110 |
Why?
| | Emphysema | 3 | 2012 | 115 | 0.110 |
Why?
| | Opioid-Related Disorders | 1 | 2023 | 582 | 0.110 |
Why?
| | CD36 Antigens | 2 | 2006 | 32 | 0.110 |
Why?
| | Biopsy | 1 | 2018 | 1068 | 0.110 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2620 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2018 | 330 | 0.100 |
Why?
| | Hyaluronan Receptors | 2 | 2006 | 104 | 0.100 |
Why?
| | United States | 8 | 2025 | 15602 | 0.100 |
Why?
| | Schistosomiasis mansoni | 1 | 2013 | 25 | 0.100 |
Why?
| | Schistosoma mansoni | 1 | 2013 | 41 | 0.100 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 65 | 0.100 |
Why?
| | Anticoagulants | 1 | 2018 | 718 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 345 | 0.100 |
Why?
| | Epithelial Cells | 3 | 2025 | 1128 | 0.100 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2016 | 245 | 0.100 |
Why?
| | Leukocytes, Mononuclear | 1 | 2016 | 580 | 0.100 |
Why?
| | Thymus Gland | 1 | 2014 | 317 | 0.090 |
Why?
| | Echocardiography | 1 | 2016 | 642 | 0.090 |
Why?
| | Biological Transport | 1 | 2014 | 412 | 0.090 |
Why?
| | Interleukin-6 | 3 | 2013 | 791 | 0.090 |
Why?
| | Respiration, Artificial | 3 | 2025 | 706 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 872 | 0.090 |
Why?
| | Mice, Transgenic | 3 | 2013 | 2182 | 0.090 |
Why?
| | Acute Disease | 1 | 2015 | 996 | 0.090 |
Why?
| | Cell Line | 4 | 2012 | 2906 | 0.090 |
Why?
| | Phosphatidylserines | 2 | 2008 | 60 | 0.090 |
Why?
| | Doxycycline | 1 | 2012 | 61 | 0.090 |
Why?
| | Acetylcysteine | 2 | 2016 | 141 | 0.090 |
Why?
| | Colitis | 1 | 2014 | 280 | 0.080 |
Why?
| | Bronchoalveolar Lavage | 3 | 2017 | 92 | 0.080 |
Why?
| | Pyrroles | 1 | 2012 | 213 | 0.080 |
Why?
| | Glucocorticoids | 1 | 2015 | 539 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1508 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 483 | 0.080 |
Why?
| | Membrane Glycoproteins | 3 | 2010 | 499 | 0.080 |
Why?
| | Erythrocytes | 2 | 2009 | 757 | 0.080 |
Why?
| | Rural Health Services | 1 | 2011 | 140 | 0.080 |
Why?
| | Adolescent | 5 | 2022 | 22233 | 0.080 |
Why?
| | In Vitro Techniques | 2 | 2002 | 1054 | 0.080 |
Why?
| | Health Care Surveys | 1 | 2011 | 535 | 0.080 |
Why?
| | Peritonitis | 1 | 2010 | 84 | 0.080 |
Why?
| | Ceramides | 1 | 2010 | 116 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2926 | 0.080 |
Why?
| | Sepsis | 3 | 2020 | 639 | 0.080 |
Why?
| | Amides | 1 | 2010 | 101 | 0.080 |
Why?
| | Membrane Proteins | 3 | 2006 | 1182 | 0.080 |
Why?
| | Stress Fibers | 1 | 2009 | 18 | 0.080 |
Why?
| | Acute Lung Injury | 1 | 2013 | 308 | 0.080 |
Why?
| | Amiloride | 1 | 2009 | 25 | 0.080 |
Why?
| | Thiazolidinediones | 1 | 2010 | 137 | 0.080 |
Why?
| | Endotoxemia | 2 | 2001 | 88 | 0.080 |
Why?
| | Phosphorylation | 1 | 2014 | 1761 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 781 | 0.070 |
Why?
| | Alcohol-Related Disorders | 1 | 2010 | 121 | 0.070 |
Why?
| | PPAR gamma | 1 | 2010 | 176 | 0.070 |
Why?
| | Oxygen Consumption | 1 | 2011 | 725 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 779 | 0.070 |
Why?
| | Prevalence | 2 | 2025 | 2819 | 0.070 |
Why?
| | Antigens, Differentiation | 1 | 2008 | 78 | 0.070 |
Why?
| | Indoles | 1 | 2012 | 479 | 0.070 |
Why?
| | Statistics, Nonparametric | 1 | 2009 | 431 | 0.070 |
Why?
| | Telephone | 1 | 2009 | 175 | 0.070 |
Why?
| | Interleukin-4 | 1 | 2008 | 212 | 0.070 |
Why?
| | Risk Factors | 4 | 2018 | 10623 | 0.070 |
Why?
| | Gene Expression | 2 | 2010 | 1512 | 0.070 |
Why?
| | Actins | 1 | 2009 | 428 | 0.060 |
Why?
| | Receptors, Immunologic | 1 | 2008 | 207 | 0.060 |
Why?
| | Blotting, Western | 1 | 2009 | 1207 | 0.060 |
Why?
| | Free Radical Scavengers | 1 | 2006 | 86 | 0.060 |
Why?
| | Hydroxymethylglutaryl CoA Reductases | 1 | 2006 | 13 | 0.060 |
Why?
| | Protein Prenylation | 1 | 2006 | 19 | 0.060 |
Why?
| | Heart Rate | 3 | 2005 | 843 | 0.060 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5761 | 0.060 |
Why?
| | Models, Biological | 1 | 2014 | 1833 | 0.060 |
Why?
| | Down-Regulation | 2 | 2025 | 641 | 0.060 |
Why?
| | Mannose-Binding Lectin | 1 | 2006 | 20 | 0.060 |
Why?
| | Lysophospholipids | 1 | 2006 | 74 | 0.060 |
Why?
| | Pyridines | 1 | 2010 | 612 | 0.060 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2006 | 119 | 0.060 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 178 | 0.060 |
Why?
| | Parenteral Nutrition | 1 | 2006 | 105 | 0.060 |
Why?
| | Protein Biosynthesis | 1 | 2008 | 454 | 0.060 |
Why?
| | Transcription, Genetic | 2 | 2010 | 1504 | 0.060 |
Why?
| | Receptors, Complement | 1 | 2006 | 121 | 0.060 |
Why?
| | omega-N-Methylarginine | 1 | 2005 | 29 | 0.060 |
Why?
| | Health Care Costs | 1 | 2009 | 416 | 0.060 |
Why?
| | Arginine | 1 | 2006 | 265 | 0.060 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2025 | 57 | 0.050 |
Why?
| | Bronchi | 1 | 2006 | 270 | 0.050 |
Why?
| | Regeneration | 1 | 2006 | 197 | 0.050 |
Why?
| | Antigens, CD | 2 | 2006 | 564 | 0.050 |
Why?
| | Patient Satisfaction | 1 | 2009 | 700 | 0.050 |
Why?
| | MAP Kinase Signaling System | 1 | 2006 | 316 | 0.050 |
Why?
| | Single-Blind Method | 3 | 2001 | 308 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2948 | 0.050 |
Why?
| | HIV Infections | 1 | 2019 | 3048 | 0.050 |
Why?
| | Blood Pressure | 3 | 2016 | 1751 | 0.050 |
Why?
| | Nitrates | 2 | 2005 | 99 | 0.050 |
Why?
| | Monocytes | 1 | 2006 | 543 | 0.050 |
Why?
| | Collagen | 1 | 2006 | 467 | 0.050 |
Why?
| | Analgesia | 1 | 2024 | 102 | 0.050 |
Why?
| | Lung Diseases | 2 | 2009 | 794 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1459 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2902 | 0.050 |
Why?
| | Fibroblasts | 1 | 2008 | 1035 | 0.050 |
Why?
| | Patient Readmission | 2 | 2019 | 724 | 0.050 |
Why?
| | Complement Activation | 1 | 2006 | 411 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 2220 | 0.050 |
Why?
| | Pulmonary Surfactant-Associated Proteins | 1 | 2002 | 9 | 0.050 |
Why?
| | Cathepsin G | 1 | 2002 | 4 | 0.050 |
Why?
| | Proteolipids | 1 | 2002 | 28 | 0.050 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 419 | 0.050 |
Why?
| | Cathepsins | 1 | 2002 | 24 | 0.050 |
Why?
| | Macromolecular Substances | 1 | 2002 | 223 | 0.050 |
Why?
| | Fever | 3 | 2001 | 311 | 0.050 |
Why?
| | Oxidative Stress | 1 | 2009 | 1377 | 0.040 |
Why?
| | Vasopressins | 1 | 2022 | 60 | 0.040 |
Why?
| | Immunotherapy | 1 | 2006 | 669 | 0.040 |
Why?
| | Heart Diseases | 1 | 2005 | 343 | 0.040 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2001 | 74 | 0.040 |
Why?
| | Colorado | 1 | 2011 | 4578 | 0.040 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2002 | 64 | 0.040 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 210 | 0.040 |
Why?
| | Vasoconstrictor Agents | 1 | 2022 | 144 | 0.040 |
Why?
| | Norepinephrine | 1 | 2022 | 193 | 0.040 |
Why?
| | Pulmonary Surfactants | 1 | 2002 | 103 | 0.040 |
Why?
| | Serine Endopeptidases | 1 | 2002 | 128 | 0.040 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 11 | 0.040 |
Why?
| | Status Asthmaticus | 1 | 2020 | 13 | 0.040 |
Why?
| | Carbon Dioxide | 2 | 2001 | 242 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2004 | 1355 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2009 | 3609 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2008 | 2045 | 0.040 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2001 | 342 | 0.040 |
Why?
| | Cell Communication | 1 | 2002 | 325 | 0.040 |
Why?
| | Rural Population | 1 | 2025 | 638 | 0.040 |
Why?
| | Vascular Resistance | 2 | 2016 | 366 | 0.040 |
Why?
| | Sputum | 1 | 2002 | 314 | 0.040 |
Why?
| | Chronic Disease | 1 | 2006 | 1826 | 0.040 |
Why?
| | Glycoproteins | 1 | 2002 | 357 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 684 | 0.040 |
Why?
| | Young Adult | 4 | 2019 | 13914 | 0.040 |
Why?
| | NADPH Oxidase 2 | 2 | 2010 | 35 | 0.040 |
Why?
| | Autoimmunity | 1 | 2006 | 925 | 0.040 |
Why?
| | Dyspnea | 1 | 2001 | 257 | 0.040 |
Why?
| | Cross-Over Studies | 2 | 1999 | 594 | 0.040 |
Why?
| | Cyclic GMP | 1 | 1999 | 92 | 0.040 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 1999 | 11 | 0.040 |
Why?
| | NADPH Oxidases | 2 | 2010 | 130 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2017 | 3614 | 0.040 |
Why?
| | Mice, Inbred BALB C | 2 | 2013 | 1270 | 0.040 |
Why?
| | Endothelium, Vascular | 2 | 2003 | 965 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 1999 | 427 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2018 | 44 | 0.030 |
Why?
| | Hospital Charges | 1 | 2017 | 45 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2004 | 1688 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 137 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 165 | 0.030 |
Why?
| | Cellular Reprogramming | 1 | 2018 | 103 | 0.030 |
Why?
| | Muscular Diseases | 1 | 2017 | 112 | 0.030 |
Why?
| | Time Factors | 2 | 2018 | 7068 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2019 | 427 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2018 | 208 | 0.030 |
Why?
| | Protein Binding | 1 | 2002 | 2261 | 0.030 |
Why?
| | Cytokines | 3 | 2013 | 2093 | 0.030 |
Why?
| | Teichoic Acids | 1 | 2016 | 18 | 0.030 |
Why?
| | Biomarkers | 2 | 2019 | 4248 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 6004 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 1996 | 214 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1638 | 0.030 |
Why?
| | Systole | 1 | 2016 | 173 | 0.030 |
Why?
| | Acute Kidney Injury | 2 | 2014 | 848 | 0.030 |
Why?
| | Risk | 1 | 2018 | 901 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2016 | 136 | 0.030 |
Why?
| | Lung Diseases, Interstitial | 1 | 2002 | 663 | 0.030 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 2 | 2009 | 42 | 0.030 |
Why?
| | Cell Membrane | 2 | 2010 | 709 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 561 | 0.030 |
Why?
| | Toll-Like Receptor 2 | 1 | 2016 | 123 | 0.030 |
Why?
| | Transcription Factors | 1 | 2003 | 1735 | 0.030 |
Why?
| | Amino Acid Oxidoreductases | 1 | 1994 | 17 | 0.030 |
Why?
| | Dogs | 2 | 2006 | 437 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 592 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 828 | 0.030 |
Why?
| | Immunologic Factors | 1 | 1996 | 256 | 0.030 |
Why?
| | Ipilimumab | 1 | 2014 | 39 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 607 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 1996 | 683 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2009 | 1192 | 0.030 |
Why?
| | Toll-Like Receptor 4 | 1 | 2016 | 277 | 0.030 |
Why?
| | Infliximab | 1 | 2014 | 108 | 0.030 |
Why?
| | Mice, 129 Strain | 1 | 2013 | 87 | 0.020 |
Why?
| | Blood Urea Nitrogen | 1 | 2013 | 52 | 0.020 |
Why?
| | Hemorrhage | 1 | 2018 | 799 | 0.020 |
Why?
| | Phylogeny | 1 | 2017 | 1011 | 0.020 |
Why?
| | Hypotension | 1 | 2014 | 127 | 0.020 |
Why?
| | Diarrhea | 1 | 2014 | 188 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2095 | 0.020 |
Why?
| | Endothelial Cells | 2 | 2010 | 858 | 0.020 |
Why?
| | Cardiac Catheterization | 1 | 2016 | 531 | 0.020 |
Why?
| | Transfection | 2 | 2006 | 952 | 0.020 |
Why?
| | Vasoconstriction | 1 | 2013 | 219 | 0.020 |
Why?
| | Antioxidants | 1 | 2016 | 580 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 2 | 2010 | 2522 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2018 | 700 | 0.020 |
Why?
| | Pulmonary Circulation | 1 | 2013 | 431 | 0.020 |
Why?
| | Trachea | 1 | 2013 | 256 | 0.020 |
Why?
| | Creatinine | 1 | 2013 | 492 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 1999 | 3392 | 0.020 |
Why?
| | Ceramidases | 1 | 2010 | 4 | 0.020 |
Why?
| | Zymosan | 1 | 2010 | 39 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2013 | 1308 | 0.020 |
Why?
| | Nitric Oxide Synthase | 2 | 2005 | 240 | 0.020 |
Why?
| | Lung Compliance | 1 | 2009 | 45 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 81 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2010 | 2847 | 0.020 |
Why?
| | Gene Deletion | 1 | 2010 | 388 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 991 | 0.020 |
Why?
| | Rats | 2 | 2010 | 5609 | 0.020 |
Why?
| | 3T3 Cells | 1 | 2008 | 158 | 0.020 |
Why?
| | Capillaries | 1 | 2009 | 124 | 0.020 |
Why?
| | Binding, Competitive | 1 | 2008 | 192 | 0.020 |
Why?
| | Leukocytes | 1 | 2009 | 293 | 0.020 |
Why?
| | Pulmonary Emphysema | 1 | 2010 | 310 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2009 | 311 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 856 | 0.020 |
Why?
| | Melanoma | 1 | 2014 | 806 | 0.020 |
Why?
| | ATP Binding Cassette Transporter 1 | 1 | 2006 | 10 | 0.020 |
Why?
| | Receptors, LDL | 1 | 2006 | 53 | 0.020 |
Why?
| | Gene Targeting | 1 | 2006 | 83 | 0.020 |
Why?
| | Syk Kinase | 1 | 2006 | 22 | 0.020 |
Why?
| | Fetal Distress | 1 | 2006 | 14 | 0.020 |
Why?
| | Random Allocation | 1 | 2006 | 364 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 109 | 0.010 |
Why?
| | Immunity | 1 | 2006 | 139 | 0.010 |
Why?
| | Nitrites | 1 | 2005 | 89 | 0.010 |
Why?
| | Hyperoxia | 1 | 2006 | 99 | 0.010 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2006 | 105 | 0.010 |
Why?
| | RNA Interference | 1 | 2006 | 482 | 0.010 |
Why?
| | Tumor Suppressor Proteins | 1 | 2006 | 324 | 0.010 |
Why?
| | Caenorhabditis elegans Proteins | 1 | 2006 | 208 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2006 | 1032 | 0.010 |
Why?
| | Child | 2 | 2021 | 22440 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2003 | 100 | 0.010 |
Why?
| | Survival Analysis | 1 | 2006 | 1358 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2006 | 1305 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2006 | 435 | 0.010 |
Why?
| | Homeostasis | 1 | 2006 | 638 | 0.010 |
Why?
| | Chimera | 1 | 2002 | 61 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2006 | 1096 | 0.010 |
Why?
| | Neutrophil Infiltration | 1 | 2002 | 105 | 0.010 |
Why?
| | Stroke Volume | 1 | 2005 | 617 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2006 | 2017 | 0.010 |
Why?
| | Hypoxia | 1 | 2009 | 1199 | 0.010 |
Why?
| | Neovascularization, Physiologic | 1 | 2003 | 196 | 0.010 |
Why?
| | Interleukin-1 | 2 | 1996 | 962 | 0.010 |
Why?
| | Respiratory Muscles | 1 | 2001 | 35 | 0.010 |
Why?
| | Cell Count | 1 | 2002 | 324 | 0.010 |
Why?
| | Blood Gas Analysis | 1 | 2001 | 84 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2005 | 832 | 0.010 |
Why?
| | Cell Division | 1 | 2003 | 780 | 0.010 |
Why?
| | Chemokines | 1 | 2002 | 224 | 0.010 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2002 | 179 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 2003 | 499 | 0.010 |
Why?
| | Bone Marrow Transplantation | 1 | 2002 | 294 | 0.010 |
Why?
| | Bleomycin | 1 | 2002 | 246 | 0.010 |
Why?
| | Hyaluronic Acid | 1 | 2002 | 210 | 0.010 |
Why?
| | Proteins | 1 | 2006 | 1023 | 0.010 |
Why?
| | Chemokine CCL3 | 1 | 1999 | 17 | 0.010 |
Why?
| | Chemokine CCL4 | 1 | 1999 | 22 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1733 | 0.010 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 1999 | 80 | 0.010 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 1999 | 166 | 0.010 |
Why?
| | Shivering | 1 | 1996 | 5 | 0.010 |
Why?
| | Acute-Phase Reaction | 1 | 1996 | 37 | 0.010 |
Why?
| | Blood Cell Count | 1 | 1996 | 53 | 0.010 |
Why?
| | Toxemia | 1 | 1996 | 4 | 0.010 |
Why?
| | Lactoferrin | 1 | 1996 | 36 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 1996 | 158 | 0.010 |
Why?
| | Solubility | 1 | 1996 | 239 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 254 | 0.010 |
Why?
| | Kinetics | 1 | 1999 | 1622 | 0.010 |
Why?
| | Calmodulin | 1 | 1994 | 71 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2006 | 6362 | 0.010 |
Why?
| | Cytosol | 1 | 1994 | 225 | 0.010 |
Why?
| | Phenotype | 1 | 2002 | 3183 | 0.010 |
Why?
| | Electrocardiography | 1 | 1996 | 635 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1996 | 706 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2006 | 2636 | 0.010 |
Why?
| | Cattle | 1 | 1994 | 1004 | 0.010 |
Why?
| | Hemodynamics | 1 | 1996 | 1116 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1994 | 791 | 0.010 |
Why?
| | Sulfonamides | 1 | 1994 | 574 | 0.010 |
Why?
| | Prospective Studies | 1 | 1996 | 7900 | 0.000 |
Why?
|
|
Vandivier's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|